Epigenetics application in the diagnosis and treatment of bladder cancer

Canadian Journal of Urology

Volumn 22, Issue 5, 2015, Pages 7947-7951

  Harb De la Rosa, Alfredo ^a   Acker, Matthew ^a   Kumar, Raj A ^a   Manoharan, Murugesan ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Bladder cancer; DNA methylation; Histone acetylation; microRNA regulation

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; METHYLTRANSFERASE; MICRORNA; TUMOR MARKER;

ANTAGONISTS AND INHIBITORS; DNA METHYLATION; EPIGENETICS; GENETIC EPIGENESIS; GENETICS; HISTONE CODE; HUMAN; PROGNOSIS; URINARY BLADDER NEOPLASMS;

BIOMARKERS, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; HISTONE CODE; HISTONE DEACETYLASE INHIBITORS; HUMANS; METHYLTRANSFERASES; MICRORNAS; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 84946780205     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Negraes PD, Favaro FP, Camargo JL et al. DNA methylation patterns in bladder cancer and washing cell sediments: a perspective for tumor recurrence detection. BMC Cancer 2008;8:238.
2. Starke N, Singla N, Haddad A, Lotan Y. Long-term outcomes of high risk bladder cancer screening cohort. BJU Int 2015;April 18. Epub ahead of print.
3. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9-29.
4. van Lingen AV, Witjes JA. Current intravesical therapy for non-muscle invasive bladder cancer. Expert Opin Biol Ther 2013;13(10):1371-1385.
5. Jin Y, Lu J, Wen J, Shen Y, Wen X. Regulation of growth of human bladder cancer by miR-192. Tumour Biol 2015;36(5):3791-3797.
6. Marsit CJ, Houseman EA, Christensen BC et al. Identification of methylated genes associated with aggressive bladder cancer. PLoS One 2010;5(8):e12334.
7. Whayne TF. Epigenetics in the development, modification, and prevention of cardiovascular disease. Mol Biol Rep 2015;42(4):765-776.
8. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004;22(22):4632-4642.
9. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429(6990):457-463.
10. Hoffman AM, Cairns P. Epigenetics of kidney cancer and bladder cancer. Epigenomics 2011;3(1):19-34.
11. Wang X, Zhang L, Ding N et al. Identification and characterization of DNAzymes targeting DNA methyltransferase I for suppressing bladder cancer proliferation. Biochem Biophys Res Commun 2015;461(2):329-333.
12. Grange C, Collino F, Tapparo M, Camussi G. Oncogenic micro-RNAs and renal cell carcinoma. Front Oncol 2014;4:49.
13. Dudziec E, Miah S, Choudhry HM et al. Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer. Clin Cancer Res 2011;17(6):1287-1296.
14. Neuhausen A, Florl AL, Grimm MO, Schulz WA. DNA methylation alterations in urothelial carcinoma. Cancer Biol Ther 2006;5(8):993-1001.
15. Manoharan M, Ramachandran K, Soloway MS, Singal R. Epigenetic targets in the diagnosis and treatment of prostate cancer. Int Braz J Urol 2007;33(1):11-18.
16. Woo HD, Kim J. Global DNA hypomethylation in peripheral blood leukocytes as a biomarker for cancer risk: a meta-analysis. PLoS One 2012;7(4):e34615.
17. Patchsung M, Broonla C, Amnattrakul P et al. Long interspersed nuclear element-1 hypomethylation and oxidative stress: correlation and bladder cancer diagnostic potential. PLoS One 2012;7(5):e37009.
18. Gowrishankar B, Ibragimova I, Zhou Y et al. MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol Ther 2014;15(3):329-341.
19. Mahdavinezhad A, Mousavi-Bahar SH, Poorolajal J et al. Evaluation of miR-141, miR-200c, miR-30b Expression and Clinicopathological Features of Bladder Cancer. Int J Mol Cell Med 2015;4(1):32-39.
20. Yu G, Yao W, Xiao W, Li H, Xu H, Lang B. MicroRNA-34a functions as an anti-metastatic microRNA and suppresses angiogenesis in bladder cancer by directly targeting CD44. J Exp Clin Cancer Res 2014;33(1):779.
21. Dudziec E, Gogol-Doring A, Cookson V, Chen W, Catto, J. Integrated epigenome profiling of repressive histone modifications, DNA methylation and gene expression in normal and malignant urothelial cells. PLoS One 2012;7(3):e32750.
22. Garibyan L, Avashia N. Polymerase chain reaction. J Invest Dermatol 2013;133(3):e6.
23. Andres G, Ashour N, Sanchez-Chapado M, Ropero S, Angulo JC. The study of DNA methylation in urological cancer: present and future. Actas Urol Esp 2013;37(6):368-375.
24. Chen PC, Tsai MH, Yip SK et al. Distinct DNA methylation epigenotypes in bladder cancer from different Chinese subpopulations and its implication in cancer detection using voided urine. BMC Med Genomics 2011;4:45.
25. Chung W, Bondaruk J, Jelinek J et al. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol Biomarkers Prev 2011;20(7):1483-1491.
26. Yu J, Zhu T, Wang Z et al. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res 2007;13(24):7296-7304.
27. Costa VL, Henrique R, Danielsen SA et al. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res 2010;16(23):5842-5851.
28. Cebrian V, Fierro M, Orenes-Piñero E et al. KISS1 methylation and expression as tumor stratification biomarkers and clinical outcome prognosticators for bladder cancer patients. Am J Pathol 2011;179(2):540-546.
29. Sheikhnejad G, Brank A, Christman JK et al. Mechanism of inhibition of DNA (cytosine C5)-methyltransferases by oligodeoxyribonucleotides containing 5,6-dihydro-5-azacytosine. J Mol Biol 1999;285(5):2021-2034.
30. Brank AS, Eritja R, Garcia RG et al. Inhibition of HhaI DNA (Cytosine-C5) methyltransferase by oligodeoxyribonucleotides containing 5-aza-2'-deoxycytidine: examination of the intertwined roles of co-factor, target, transition state structure and enzyme conformation. J Mol Biol 2002;323(1):53-67.
31. Cheng JC, Matsen CB, Gonzales FA et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 2003;95(5):399-409.
32. Hurd PJ, Whitmarsch AJ, Baldwin GS et al. Mechanism-based inhibition of C5-cytosine DNA methyltransferases by 2-H pyrimidinone. J Mol Biol 1999;286(2):389-401.
33. Zhou L, Cheng X, Connolly BA et al. Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 2002;321(4):591-599.
34. O'Rourke CJ, Knabben V, Bolton E et al. Manipulating the epigenome for the treatment of urological malignancies. Pharmacol Ther 2013;138(2):185-196.
35. Adam RM. Histone deacetylase inhibitors and bladder cancer. J Urol 2010;183(6):2120-2121.
36. Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 2005;97(2):103-115.
37. Martin-Doyle W, Kwiatkowski DJ. Molecular biology of bladder cancer. Hematol Oncol Clin North Am 2015;29(2):191-203.
38. Andersen A, Jones DA. APC and DNA demethylation in cell fate specification and intestinal cancer. Adv Exp Med Biol 2013;754:167-177.
39. Fernandes MS, Carneiro F, Oliveira C, Seruca R. Colorectal cancer and RASSF family--a special emphasis on RASSF1A. Int J Cancer 2013;132(2):251-258.
40. Elzi DJ, Song M, Hakala K, Weintraub ST, Shiio Y. Wnt antagonist SFRP1 functions as a secreted mediator of senescence. Mol Cell Biol 2012;32(21):4388-4399.
41. Zimmers TA, Jin X, Hsiao EC et al. Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock 2005;23(6):543-548.
42. Filipczak PT, Piglowski W, Glowala-Kosinska M, Krawczyk Z, Scieglinska D. HSPA2 overexpression protects V79 fibroblasts against bortezomib-induced apoptosis. Biochem Cell Biol 2012;90(2):224-231.
43. Lin K, Taylor JR Jr, Wu TD et al. TMEFF2 is a PDGF-AA binding protein with methylation-associated gene silencing in multiple cancer types including glioma. PLoS One 2011;6(4):e18608.
44. Boimel PJ, Cruz C, Segall JE. A functional in vivo screen for regulators of tumor progression identifies HOXB2 as a regulator of tumor growth in breast cancer. Genomics 2011;98(3):164-172.
45. Yamada A, Iwata T, Yamato M, Okano T, Izumi Y. Diverse functions of secreted frizzled-related proteins in the osteoblastogenesis of human multipotent mesenchymal stromal cells. Biomaterials 2013;34(13):3270-3278.